N/A N=408 Integrating Pharmacogenetics In Clinical Care
Cardiovascular Disease
Primary: 12-Month Change in LDL Cholesterol — -1.1; -2.2 mg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=531 Implementing Pharmacogenetic Testing in Gastrointestinal Cancers
Gastrointestinal Cancer
Primary: Feasibility: Number and Percentage of Participants Who Had Their Pharmacogenetic Tests Returned Prior to Initial Dose — 130; 95 Participants
N/A N=88 Pharmacogenetics of b2-Agonists in Asthma.
Asthma
Primary: Log10 PC20 to Methacholine After Visit 2 — 0.54; 0.48; 0.16; 0.53 log10 mg/mL — p=0.27
Phase 4 N=105 Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery
Pain · Other Surgical Procedures · Impacted Third Molar Tooth
Primary: Score of Pain Measured by Visual Analogue Scale — 25 score on a scale (mm)
N/A N=110 Pharmacogenetic Testing Among Home Health Patients
Adverse Drug Events · Adverse Drug Reactions · Drug Interaction Potentiation
Primary: Number of Re-hospitalizations at 30 and 60 Days — 0.38; 0.25; 0.7; 0.33 Re-hospitalizations — p=0.21
N/A N=18 Clopidogrel Pharmacogenetics (PGX) Bench to Bedside
Metabolism of Clopidogrel
Primary: Change in Platelet Aggregation Following Therapy With Clopidogrel — 62.9; 68.1; 62.5; 63.2 percentage of aggregation
N/A N=112 Pharmacogenetic-guided Choice of Post-surgery Analgesics
Acute Pain · Post Operative Pain
Primary: Feasibility of Integrating a PGx Panel Test in the EMR With a Pharmacist Consult Note for Each Patient — 35; 0 Participants
Phase 4 N=28 Implementation of PPI Medication PGX Testing
Gastroesophageal Reflux
Primary: Count of Patients Agreeing to Volunteer for the Study — 28 Participants
N/A N=190 Delivery of Pharmacogenetic Testing in a Community Pharmacy Setting
Pharmacogenetics
Primary: Number of Patient Participants' Acceptance of PGx Services Offered in Community Pharmacy Setting — 14; 13 Participants
Phase 4 N=19 Pharmacogenomics of Antiplatelet Response - I
Platelet Aggregation · Platelet Transcriptome · Coronary Artery Disease
Primary: Difference in ADP-induced Platelet Aggregation — -5.2 Difference in ohms (Post-Pre)
N/A N=53 Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population
Pharmacogenetic Testing
Primary: Clinical Global Impression — 4.07; 3.96 units on a scale — p=<0.05
Phase 3 N=49 Pharmacogenomics in Autism Treatment
Autism
Primary: Percent Change of ABC - Irritability Subscale Score — -44.5 percent change in scores
N/A N=114 Pharmacogenomics of Thiazolidinediones
Type 2 Diabetes
Primary: Change in Insulin Resistance — -0.83 HOMA-IR index is unitless by definition — p=<0.0000001
N/A N=70 Pharmacogenomic Testing to Personalize Supportive Oncology
Cancer · Depression · Pain
Primary: Proportion of Participants Receiving at Least One Drug/Dose Selection or Modification Based on PGx Results — 9 Participants
Phase 4 N=92 Pharmacogenomics and Post-Operative Nausea and Vomiting
Postoperative Nausea
Primary: Episodes of Postoperative Nausea — 0; 16 episodes
N/A N=29 Pharmacogenetics of Warfarin Induction and Inhibition
Healthy
Primary: Warfarin Clearance. — 282; 246; 180; 84 mL/h — p=<0.0001
N/A N=204 Evaluation of Pharmacogenetic Factors Affecting Fentanyl Requirements for Postoperative Pain Control
Pain, Postoperative
Primary: Postoperative Cumulative Fentanyl Consumption — 836 mcg
N/A N=100 Pilot of Preemptive Pharmacogenetics in Medically Underserved Patients
Pharmacogenetic Testing
Primary: Change in Global Patient Treatment Satisfaction Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM) — 59.9; 64.4 score on a scale — p=0.001
Phase 3 N=2,415 Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin
Thromboembolism
Primary: The Percent of Out of Range (OOR) International Normalized Prothrombin Time Ratio (INRs) in the Standard and Modified Pharmacogenetic Arms. — 30.6; 31.8 percent — p=<0.05
N/A N=104 Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm
Depression · Anxiety
Primary: Number of Outpatient Visits — 13 units on a scale
Phase 4 N=8 Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients
Kidney Transplantation
Primary: Tacrolimus Bioavailability (F) — 0.224; 0.681 ratio of oral to IV — p=0.006
Phase 4 N=34 Pharmacogenomics of Antiplatelet Response
Atherosclerosis
Primary: Differential Gene Expression — 77.1 FPKM for HBG1 Gene — p=<0.000005
N/A N=227 Evaluation of an Antidepressant Pharmacogenomic Algorithm in an Outpatient Clinical Setting
Depression
Primary: Percentage Change in Quick Inventory of Depressive Symptomatology (QIDS-C16) Score From Baseline — -41.2; -11.0; -48.4; -31.8 Percentage change in depression rating…
Phase 4 N=23 Genetic Basis for Variation in the Renal Elimination of Metformin
Other Conditions That May Be A Focus of Clinical Attention
Primary: Renal Clearance of Metformin — 614; 441 mL/min
Phase 3 N=254 Pharmacogenetics, Emotional Reactivity and Smoking
Tobacco Use Disorder · Smoking Cessation
Primary: Emotional Reactivity By Pharmacotherapy — 66.6; 64.7; 65.6; 70.9 microvolts
N/A N=75 Pharmacogenomic Testing in Primary Care
Antidepressants Causing Adverse Effects in Therapeutic Use
Primary: Count of Participants Prescribed Antidepressant Medication — 5; 8; 5; 8 Participants
Phase 3 N=1,246 Pharmacogenetics of Nicotine Addiction Treatment
Nicotine Addiction
Primary: 7-day Point Prevalence Quit Rate at End-of-Treatment (EOT) — 17.2; 18.6; 27.7; 22.5 percentage of ITT subjects
N/A N=159 Genetically Guided Statin Therapy
Hypercholesterolemia · Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction
Primary: Morisky Medication Adherence Scale (MMAS) Score — 6.8; 6.9; 6.8; 7.1 units on a scale — p=0.96
Phase 4 N=888 Pharmacogenomic Evaluation of Antihypertensive Responses
Hypertension
Primary: Blood Pressure Response (Delta BP (After 18 Weeks of Medication - Baseline)). — -12.06; -13.33 mmHg
N/A N=263 Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)
Venous Thromboembolism · Bleeding
Primary: The Number of Participants With Adverse Events Associated With Warfarin Anticoagulation Following Total Hip and Total Knee Replacement — 2; 4 participants